Sign In
Buy TNDM
$18.03
-0.570 (-3.06%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - November 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tan
New York, New York--(Newsfile Corp. - November 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tan
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- WHY: November 12, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders o
Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
09:00am, Wednesday, 12'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
08:08pm, Tuesday, 11'th Nov 2025
NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care,
New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ta
Tandem Mobi Receives FDA Clearance for Use with Android Smartphones
08:30am, Monday, 10'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administ
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
09:16pm, Thursday, 06'th Nov 2025
Tandem Diabetes Care, Inc. ( TNDM ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
07:31pm, Thursday, 06'th Nov 2025
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Thursday, 06'th Nov 2025
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
04:20pm, Thursday, 06'th Nov 2025
NEW YORK , Nov. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care,
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 3
